News
-
Irish science center AMBER (Advanced Materials and BioEngineering Research), located at Trinity College Dublin, has announced that investigator Anne Marie Healy has received a €600,000 grant from the US National Institutes of Health (NIH) for… Read more . . .
-
Mucosis has initiated a Phase 1 study of its SynGEM intranasal respiratory syncytial virus (RSV) vaccine, the company said. In January 2016, Mucosis announced that it had received a €3.7 million grant from the Wellcome… Read more . . .
-
Submit 500 word abstracts by February 11, 2017. See http://www.inhalationasia.org/conference/inhalation-asia-2017-from-13-to-15-september-2017-in-Hong-Kong/present for a list of topics and submission form. Read more . . .
-
According to numerous sources, Teleflex Medical has voluntarily recalled multiple lots of its LMA MAD intranasal delivery device because the devices are failing to aerosolize the drug. The recall notification says, “Teleflex Medical is recalling… Read more . . .
-
Propeller Health has announced that its inhaler monitoring platform has received 510(k) clearance from the FDA for use with the Ellipta dry powder inhaler. The company had announced a deal with GSK to develop a… Read more . . .
-
Inhaler testing automation company Astech Projects has announced the delivery of a fully automated robotic workstation for shot weight testing of DPIs based on its Xelair 1 Series automation platform. The system rotates each device… Read more . . .
-
Spyryx Biosciences has presented data from preclinical studies of its SPX-101 inhaled SPLUNC1-derived peptide showing that SPX-101 improves mucus clearance and survival in animal models of cystic fibrosis and demonstrated no toxicity. The data were… Read more . . .
-
Connected device company Cohero Health has closed a $9M Series A financing round to fund development of its BreatheSmart platform, business development, and clinical trials, the company said. One of the company’s new investors is… Read more . . .
-
Inhaled drug developer Savara Pharmaceuticals has announced the appointment of former Edgemont Pharmaceuticals CFO David L. Lowrance as its new Chief Financial Officer. Savara cited Lowrance’s experience leading IPOs for Acucela, where he was CFO… Read more . . .
-
Arch Biopartners has announced that Dr. Ralph Panos of the Cincinnati Veterans Affairs Medical Center (CVAMC) will prepare a protocol for human trials of the company’s AB569 inhaled bactericide and will subsequently prepare an application… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany